Cytotoxicity, Immunologic

"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.

Descriptor ID	D003602
MeSH Number(s)	G12.287
Concept/Terms	Cytotoxicity, Immunologic Cytotoxicity, Immunologic Immunologic Cytotoxicity Immunologic Tumoricidal Activities Immunologic Tumoricidal Activities Tumoricidal Activities, Immunologic Tumoricidal Activity, Immunologic Immunologic Tumoricidal Activity

Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".

Biological Sciences [G]
Immune System Phenomena [G12]
Cytotoxicity, Immunologic [G12.287]

Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.

Bar chart showing 76 publications over 25 distinct years, with a maximum of 6 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	2	3
1996	3	2	5
1997	2	0	2
1998	1	4	5
1999	0	1	1
2000	1	3	4
2001	0	3	3
2003	0	4	4
2004	2	3	5
2005	2	1	3
2006	1	1	2
2007	1	4	5
2008	1	2	3
2009	2	2	4
2010	2	4	6
2011	0	2	2
2012	2	0	2
2014	1	2	3
2016	1	0	1
2017	1	0	1
2018	3	0	3
2019	1	2	3
2020	1	1	2
2021	1	1	2
2024	0	2	2

Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.

Chowdhury SR, Murphy KC, Parikh CN, DeMarco KD, Zhou L, Ruscetti M. Measuring the impact of therapy-induced senescence on NK cell phenotypes in cancer. Methods Cell Biol. 2024; 190:171-201.

View in: PubMed
Collins DR, Olatotse MJ, Racenet ZJ, Arshad U, ?akan E, Gaiha GD, Clayton KL, Walker BD. Expanded Antigen-Specific Elimination Assay to Measure Human CD8+ T Cell Cytolytic Potential. Curr Protoc. 2024 Jul; 4(7):e1109.

View in: PubMed
Tib?rcio R, Barreto-Duarte B, Naredren G, Queiroz ATL, Anbalagan S, Nayak K, Ravichandran N, Subramani R, Antonelli LRV, Satagopan K, Anbalagan K, Porter BO, Sher A, Swaminathan S, Sereti I, Andrade BB. Dynamics of T-Lymphocyte Activation Related to Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in Persons With Advanced HIV. Front Immunol. 2021; 12:757843.

View in: PubMed
Junqueira C, Polidoro RB, Castro G, Absalon S, Liang Z, Sen Santara S, Crespo ?, Pereira DB, Gazzinelli RT, Dvorin JD, Lieberman J. ?d T cells suppress Plasmodium falciparum blood-stage infection by direct killing and phagocytosis. Nat Immunol. 2021 03; 22(3):347-357.

View in: PubMed
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, Vangos NE, Yeoh ZC, Geffken EA, Seo HS, Liu ZX, Heffron GJ, Shah K, Dhe-Paganon S, Abdi R. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell. 2020 11 25; 183(5):1219-1233.e18.

View in: PubMed
Leite NC, Sintov E, Meissner TB, Brehm MA, Greiner DL, Harlan DM, Melton DA. Modeling Type 1 Diabetes In?Vitro Using Human Pluripotent Stem Cells. Cell Rep. 2020 07 14; 32(2):107894.

View in: PubMed
Daniels KA, O'Donnell CL, Castonguay C, Strutt TM, McKinstry KK, Swain SL, Welsh RM. Virus-induced natural killer cell lysis of T cell subsets. Virology. 2020 01 02; 539:26-37.

View in: PubMed
Koumantou D, Barnea E, Martin-Esteban A, Maben Z, Papakyriakou A, Mpakali A, Kokkala P, Pratsinis H, Georgiadis D, Stern LJ, Admon A, Stratikos E. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1). Cancer Immunol Immunother. 2019 Aug; 68(8):1245-1261.

View in: PubMed
Becerra-Artiles A, Cruz J, Leszyk JD, Sidney J, Sette A, Shaffer SA, Stern LJ. Naturally processed HLA-DR3-restricted HHV-6B peptides are recognized broadly with polyfunctional and cytotoxic CD4 T-cell responses. Eur J Immunol. 2019 08; 49(8):1167-1185.

View in: PubMed
Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018 12 21; 362(6421):1416-1422.

View in: PubMed

People

Explore

Similar Concepts

Top Journals